Novel transferrin modified and doxorubicin loaded Pluronic 85/lipid-polymeric nanoparticles for the treatment of leukemia: In vitro and in vivo therapeutic effect evaluation

Zhu, Bo; Zhang, Huanying; Yu, Liu

doi:10.1016/j.biopha.2016.11.121

Cited by 34 publications

(20 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Secondly, although the APL mouse model has been successfully established in our group, it failed to perform in the present study. The tumor bearing mice model established by HL60 cells applied in this experiment has been used for other previous studies ( 21 ), which can also certify the pro-apoptotic effects of blue light in human promyelocytic leukemia. Moreover, our present data failed to systemically discuss the correlation between MMP depolarization and ROS production during blue light mediated pro-apoptosis in HL60 cells.…”

Section: Discussionmentioning

confidence: 99%

Blue light-induced apoptosis of human promyelocytic leukemia cells via the mitochondrial-mediated signaling pathway

et al. 2018

View full text Add to dashboard Cite

Acute promyelocytic leukemia is frequently associated with dizziness, fever, nausea, hematochezia and anemia. Blue light, or light with wavelengths of 400–480 nm, transmits high levels of energy. The aim of the present study was to determine the pro-apoptotic effects of blue light (wavelength, 456 nm; radiation power, 0.25 mW/cm2) and the underlying mechanisms in a human promyelocytic leukemia cell line (HL60). Blue light reduced the viability and enhanced the mortality of HL60 cells in a time-dependent manner. Exposure to blue light for 24 h caused depolarization of the mitochondrial membrane potential and the overproduction of reactive oxygen species in HL60 cells. In a nude mouse model, 9-day exposure to blue light markedly suppressed the growth of HL60-xenografted tumors; however, it had no effect on hepatic and renal tissues. In addition, blue light abrogated the expression of B-cell lymphoma (Bcl)-2 and Bcl extra-long, while enhancing the levels of Bcl-2-associated X protein, cytochrome c, and cleaved caspases-3 and −9 in tumor tissues. The results suggested that the pro-apoptotic effects of blue light in human promyelocytic leukemia cells may be associated with the mitochondrial apoptosis signaling pathway.

show abstract

Section: Discussionmentioning

confidence: 99%

Blue light-induced apoptosis of human promyelocytic leukemia cells via the mitochondrial-mediated signaling pathway

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Multifunctional lipid-polymeric NPs loaded with doxorubicin and obtained by the nanoprecipitation method have also been developed [77]. In this strategy, doxorubicin was encapsulated in a polymeric core comprising PLGA and Pluronic® 85 (co-polymers based on ethylene oxide and propylene oxide).…”

Section: Nanoparticles Based On Polymersmentioning

confidence: 99%

Advances in treatment formulations for acute myeloid leukemia

Briot

Roger

Thépot

et al. 2018

Drug Discovery Today

View full text Add to dashboard Cite

Acute myeloid leukemia (AML) is the most common cause of leukemia-related mortality. The combination of cytarabine and anthracycline has been the gold standard of treatment over the past 40 years, but the distribution of the drugs in the body leads to severe adverse effects. Poor prognosis of older patients with AML is the consequence not only of comorbidities, but also of chemoresistance resulting from frequent secondary AML. Numerous strategies using nanotechnologies are in development to improve drug targeting, pharmacokinetics, administration route, chemoresistance, and adverse effects generally observed. Among the four new drugs approved for AML by the US Food and Drug Administration (FDA) in 2017, Vyxeos is a novel liposomal formulation of historical AML drugs. Here, we review current AML treatments and discuss how the development of new formulations will change the therapeutic armamentarium.

show abstract

“…Compared to healthy cells, transferrin receptors are abundantly expressed in cancer cells [ 80 ]. Owing to the overexpression of TfRs, transferrin ligand can bind to TfRs, leading to targeted anticancer therapy [ 81 ]. Normally, transferrin conjugation is used to target different types of malignant cells [ 82 ].…”

Section: Active Targeting With Surface Engineered Plhnpsmentioning

confidence: 99%

Utilization of Polymer-Lipid Hybrid Nanoparticles for Targeted Anti-Cancer Therapy

2020

View full text Add to dashboard Cite

Cancer represents one of the most dangerous diseases, with 1.8 million deaths worldwide. Despite remarkable advances in conventional therapies, these treatments are not effective to completely eradicate cancer. Nanotechnology offers potential cancer treatment based on formulations of several nanoparticles (NPs). Liposomes and polymeric nanoparticle are the most investigated and effective drug delivery systems (DDS) for cancer treatment. Liposomes represent potential DDS due to their distinct properties, including high-drug entrapment efficacy, biocompatibility, low cost, and scalability. However, their use is restricted by susceptibility to lipid peroxidation, instability, burst release of drugs, and the limited surface modification. Similarly, polymeric nanoparticles show several chemical modifications with polymers, good stability, and controlled release, but their drawbacks for biological applications include limited drug loading, polymer toxicity, and difficulties in scaling up. Therefore, polymeric nanoparticles and liposomes are combined to form polymer-lipid hybrid nanoparticles (PLHNPs), with the positive attributes of both components such as high biocompatibility and stability, improved drug payload, controlled drug release, longer circulation time, and superior in vivo efficacy. In this review, we have focused on the prominent strategies used to develop tumor targeting PLHNPs and discuss their advantages and unique properties contributing to an ideal DDS.

show abstract

Novel transferrin modified and doxorubicin loaded Pluronic 85/lipid-polymeric nanoparticles for the treatment of leukemia: In vitro and in vivo therapeutic effect evaluation

Cited by 34 publications

References 41 publications

Blue light-induced apoptosis of human promyelocytic leukemia cells via the mitochondrial-mediated signaling pathway

Blue light-induced apoptosis of human promyelocytic leukemia cells via the mitochondrial-mediated signaling pathway

Advances in treatment formulations for acute myeloid leukemia

Utilization of Polymer-Lipid Hybrid Nanoparticles for Targeted Anti-Cancer Therapy

Contact Info

Product

Resources

About